

August 6, 2025

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Launch of Eculizumab (Soliris)

We refer to our earlier communication dated January 16, 2025, intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Eculizumab concentrate for solution for infusion 300 mg (10mg/ml) (SOLIRIS).

With regard to the same, we wish to further update that AstraZeneca Pharma India Limited will launch Eculizumab (Soliris) in August 2025 in India.

Eculizumab (Soliris) is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) to inhibit complement – mediated thrombotic microangiopathy.

We request you to take the above intimation on record.

Thanking you

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary